Clincosm LogoSign in Get a demo

Plasma Brain Natriuretic Peptide Levels in Pregnancy

Sponsor
Oklahoma State University Center for Health Sciences (Other)
Overall Status
Completed
CT.gov ID
NCT00324402
Collaborator
(none)
50
Enrollment
1
Location
22
Duration (Months)
2.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

To evaluate the maternal blood concentrations of brain natriuretic peptide (BNP) during the second and third trimesters of a normal pregnancy. We will attempt to define a normal range for pregnancy and any outliers that may serve as markers for abnormal cardiovascular physiology.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The brain natriuretic peptide (BNP) is a useful marker for volume overload, increased filling pressures and stretching of the myocardium. The current literature contains limited and unreliable information regarding normal BNP values in pregnancy. After baseline echocardiogram to detect individuals with asymptomatic structural defects, the participants will submit to 3 blood draws during the second and third trimester and at delivery to determine normal pregnancy values.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    50 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Plasma Brain Natriuretic Peptide Levels in Pregnancy
    Study Start Date :
    Aug 1, 2006
    Actual Study Completion Date :
    Jun 1, 2008

    Arms and Interventions

    Arm Intervention/Treatment
    1

    Healthy pregnant women, 18-40

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      18 Years to 40 Years
      Sexes Eligible for Study:
      Female
      Accepts Healthy Volunteers:
      Yes
      Inclusion Criteria:

      • women age 18 to 40

      • second trimester of pregnancy

      Exclusion Criteria:

      • known cardiac or valvular disease,

      • atrial fibrillation or other arrhythmia,

      • pulmonary hypertension,

      • chronic hypertension,

      • hypertensive disorders of pregnancy,

      • morbid obesity (BMI > 40 kg/meter squared)

      • history of sleep apnea

      • multiple gestation

      • known renal dysfunction

      • medications known to affect cardiac function

      • current or past abnormal echocardiogram

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 Oklahoma State University Center for Health Sciences Tulsa Oklahoma United States 74127

      Sponsors and Collaborators

      • Oklahoma State University Center for Health Sciences

      Investigators

      • Study Chair: Kimberly A Sorensen, DO, Oklahoma State University Center for Health Sciences
      • Principal Investigator: John M Beal, DO, Oklahoma State University Center for Health Sciences

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      None provided.
      Responsible Party:
      Oklahoma State University Center for Health Sciences
      ClinicalTrials.gov Identifier:
      NCT00324402
      Other Study ID Numbers:
      • 2005008
      First Posted:
      May 11, 2006
      Last Update Posted:
      Oct 5, 2020
      Last Verified:
      Oct 1, 2020
      Keywords provided by Oklahoma State University Center for Health Sciences
      brain natriuretic peptide
      pregnancy
      biomarker
      Additional relevant MeSH terms:
      Cardiomyopathies

      Study Results

      No Results Posted as of Oct 5, 2020